Abstract
Thirty severely depressed patients received daily oral doses of 75 or 100 mg. desipramine, a metabolite of imipramine. Duration of therapy averaged 3 to 4 months and dosage was decreased gradually according to individual progress. Tranquilizers were used as required to control anxiety, insomnia or agitation, and psychotherapy was given at the level indicated. Most patients had a history of several depressive episodes, hospitalizations, ECT, or poor response to numerous other drugs. In 24 patients (80%) desipramine produced a satisfactory clinical response. The new drug exerted a faster onset of action (usually 2 to 7 days) and fewer, milder side effects compared to previous use of imipramine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
